Richard Béliveau

Richard Béliveau Richard Béliveau (born 1953 in Trois-Rivières, Quebec) is currently the director of the Molecular Medicine Laboratory and a researcher in the Department of Neurosurgery at Notre-Dame Hospital. Additionally, he holds the Claude-Bertrand Chair in Neurosurgery at the Centre hospitalier de l'Université de Montréal. Provided by Wikipedia
Showing 1 - 7 results of 7 for search 'Richard Béliveau', query time: 0.03s Refine Results
  1. 1

    Title not available by Borhane Annabi, Simon Lord-Dufour, Amélie Vézina, Richard Béliveau

    Published 2012-04-01
    Get full text
    Article
  2. 2
    Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent

    Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent by Borhane Annabi, Simon Lord-Dufour, Amélie Vézina, Richard Béliveau

    Published 2012-01-01
    Get full text
    Article
  3. 3
    Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent

    Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent by Borhane Annabi, Simon Lord-Dufour, Amélie Vézina, Richard Béliveau

    Published 2012-04-01
    Get full text
    Article
  4. 4
    The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells

    The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells by Michel Demeule, Cyndia Charfi, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

    Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing by Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi

    Published 2024-02-01
    Get full text
    Article
  6. 6
    Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing

    Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing by Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi

    Published 2024-02-01
    Get full text
    Article
  7. 7
    The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers

    The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers by Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Alain Larocque, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi

    Published 2022-04-01
    Get full text
    Article

Search Tools: